SHOULD STATINS BE DISCONTINUED IN PERI-OPERATIVE PERIOD?
https://doi.org/10.21292/2078-5658-2018-15-4-86-90
Abstract
HMG-CoA (3-hydroxy-3-methyl-glutaryl-coenzyme A) reductase inhibitors, which are more known as statins, reduce the level of low density lipoproteids and total cholesterol in blood plasma. Their efficiency for primary and secondary prevention of cardiovascular disorders has been proved by numerous trials. Additionally to the main mechanism of actions, statins possess pleiotropic properties, including anti-inflammatory endothelium protection, platelet stabilization, reduction of fibrinogen concentration and prevention of neurodegenerative and oncological disorders. Despite the vigilance of side effects, which has been growing of late, statins remain to be the drugs which are prescribed most often in the whole world. The article describes different strategies of statins use in the peri-operative period in the patients undergoing cardiac and general surgery.
About the Authors
V. V. Lomivorotov
E.N. Meshalkin Research Institute of Blood Circulation Pathology.
Russian Federation
Russian Federation
Vladimir V. Lomivorotov Correspondent Member of RAS, Doctor of Medical Sciences, Professor, Deputy Director for Research, Head of Anesthesiology and Intensive Care Center.
15, Rechkunovskaya St., Novosibirsk, 630055.
S. M. Efremov
E.N. Meshalkin Research Institute of Blood Circulation Pathology.
Russian Federation
Russian Federation
Sergey M. Efremov Doctor of Medical Sciences, Anesthesiologist and Emergency Physician of Anesthesiology and Intensive Care Department.
15, Rechkunovskaya St., Novosibirsk, 630055.
M. N. Abubakirov
E.N. Meshalkin Research Institute of Blood Circulation Pathology.
Russian Federation
Russian Federation
Marat N. Abubakirov Anesthesiologist and Emergency Physician of Anesthesiology and Intensive Care Department.
15, Rechkunovskaya St., Novosibirsk, 630055.
D. N. Merekin
E.N. Meshalkin Research Institute of Blood Circulation Pathology.
Russian Federation
Russian Federation
Dmitry N. Merekin Anesthesiologist and Emergency Physician of Anesthesiology and Intensive Care Department.
15, Rechkunovskaya St., Novosibirsk, 630055.
References
1. Lomivorotov V.V., Efremov S.M., Аbubakirov M.N. et al. Is it worth to discontinue drugs blocking the activity of renin-angiotensin-aldosterone system in the peri-operative period? Vestn. Anesteziologii I Reanimatologii, 2018, vol. 15, no. 3, (in print).
2. Bellomo R., Auriemma S., Fabbri A. et al. The pathophysiology of cardiac surgery-associated acute kidney injury (CSA-AKI). Int. J. Artif. Organs., 2008, vol. 31, pp. 166-178.
3. Berwanger O., de Barros E., Silva P.G.M. et al. Atorvastatin for high-risk statin-naïve patients undergoing noncardiac surgery: The Lowering the Risk of Operative Complications Using Atorvastatin Loading Dose (LOAD) randomized trial. Am. Heart J., 2017, vol. 184, pp. 88-96.
4. Berwanger O., Le Manach Y., Suzumura E.A. et al. Association between pre-operative statin use and major cardiovascular complications among patients undergoing non-cardiac surgery: The VISION study. Eur. Heart J., 2016, vol. 37, pp. 177-185.
5. Billings F.T., Hendricks P.A., Schildcrout J.S. et al. High-dose perioperative atorvastatin and acute kidney injury following cardiac surgery: A randomized clinical trial. JAMA, 2016, vol. 315, pp. 877-888.
6. Desai H., Aronow W.S., Ahn C. et al. Incidence of perioperative myocardial infarction and of 2-year mortality in 577 elderly patients undergoing noncardiac vascular surgery treated with and without statins. Arch. Gerontol. Geriatr., 2010, vol. 51, pp. 149-151.
7. Fleisher L.A., Fleischmann K.E., Auerbach A.D. et al. 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: A report of the American College of Cardiology. American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol., 2014, vol. 64, pp. 77-137.
8. Golomb B.A., Evans M.A. Statin adverse effects: A review of the literature and evidence for a mitochondrial mechanism. Am. J. Cardiovasc. Drugs, 2008, vol. 8, pp. 373-418.
9. Kulik A., Brookhart M.A., Levin R. et al. Impact of statin use on outcomes after coronary artery bypass graft surgery. Circulation, 2008, vol. 118, pp. 1785-1792.
10. Kulik A., Ruel M., Jneid H. et al. Secondary prevention after coronary artery bypass graft surgery: A scientific statement from the American Heart Association. Circulation, 2015, vol. 131, pp. 927-964.
11. Law M., Rudnicka A.R. Statin safety: A systematic review. Am. J. Cardiol., 2006, vol. 97, pp. 52-60.
12. Le Manach Y., Godet G., Coriat P. et al. The impact of postoperative discontinuation or continuation of chronic statin therapy on cardiac outcome after major vascular surgery. Anesth. Analg., 2007, vol. 104, pp. 1326-1333.
13. London M.J., Schwartz G.G., Hur K. et al. Association of perioperative statin use with mortality and morbidity after major noncardiac surgery. JAMA Intern. Med., 2017, pp. 177, pp. 231-242.
14. O’Neal J.B., Shaw A.D., Billings F.T. Acute kidney injury following cardiac surgery: Current understanding and future directions. Crit. Care, 2016, vol. 20, pp. 187.
15. Patti G., Chello M., Candura D. et al. Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: Results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study. Circulation, 2006, vol. 114, pp. 1455–Pickering J.W., James M.T., Palmer S.C. Acute kidney injury and prognosis after cardiopulmonary bypass: A meta-analysis of cohort studies. Am. J. Kidney Dis., 2015, vol. 65, pp. 283-293.
16. Putzu A., Capelli B., Belletti A. et al. Perioperative statin therapy in cardiac surgery: A meta-analysis of randomized controlled trials. Crit. Care, 2016, vol. 20, pp. 395.
17. Rafiq A., Sklyar E., Bella J.N. Cardiac evaluation and monitoring of patients undergoing noncardiac surgery. Heal. Serv. Insights, 2017, vol. 9, pp. 1-17.
18. Raju M.G., Pachika A., Punnam S.R. et al. Statin therapy in the reduction of cardiovascular events in patients undergoing intermediate-risk noncardiac, nonvascular surgery. Clin. Cardiol., 2013, vol. 36, pp. 456-461.
19. Rezaeefar A., Shariat Moharari R., Najafi A. et al. The perioperative effects of statins in non cardiac surgeries. Arch. Anesthesiol. Crit .Care, 2015, vol. 1, pp. 130-133.
20. Russo M.W., Hoofnagle J.H., Gu J. et al. Spectrum of statin hepatotoxicity: Experience of the drug-induced liver injury network. Hepatology, 2014, vol. 60, pp. 679-686.
21. Sousa-Uva M., Head S.J., Milojevic M. et al. 2017 EACTS guidelines on perioperative medication in adult cardiac surgery. Eur. J. Cardiothorac. Surg., 2017, vol. 53, pp. 5-33.
22. Swiger K.J., Manalac R.J., Blumenthal R.S. et al. Statins and cognition: A systematic review and meta-analysis of short- and long-term cognitive effects. Mayo Clin Proc., 2013, vol. 88, pp. 1213-1221.
23. Zheng Z., Jayaram R., Jiang L. et al. Perioperative rosuvastatin in cardiac surgery. N. Engl. J. Med., 2016, vol. 374, pp. 1744-1753.
Review
For citations:
Lomivorotov V.V., Efremov S.M., Abubakirov M.N., Merekin D.N. SHOULD STATINS BE DISCONTINUED IN PERI-OPERATIVE PERIOD? Messenger of ANESTHESIOLOGY AND RESUSCITATION. 2018;15(4):86-90. (In Russ.) https://doi.org/10.21292/2078-5658-2018-15-4-86-90
Email this article 